Dihydropyrimidine dehydrogenase deficiency, a pharmacogenetic syndrome associated with potentially life-threatening toxicity following 5-fluorouracil administration.
about
High-resolution melting analysis of the common c.1905+1G>A mutation causing dihydropyrimidine dehydrogenase deficiency and lethal 5-fluorouracil toxicity.Benefit of uridine triacetate (Vistogard) in rescuing severe 5-fluorouracil toxicity in patients with dihydropyrimidine dehydrogenase (DPYD) deficiency.Screening for 392 polymorphisms in 141 pharmacogenes.Pharmacogenetics research on chemotherapy resistance in colorectal cancer over the last 20 yearsLC-MS/MS method for simultaneous analysis of uracil, 5,6-dihydrouracil, 5-fluorouracil and 5-fluoro-5,6-dihydrouracil in human plasma for therapeutic drug monitoring and toxicity prediction in cancer patients.Dihydropyrimidine dehydrogenase gene as a major predictor of severe 5-fluorouracil toxicity.Pharmacokinetically guided dose adjustment of 5-fluorouracil: a rational approach to improving therapeutic outcomes.Emerging agents for the prevention of treatment induced neutropenia in adult cancer patients.Is monitoring of plasma 5-fluorouracil levels in metastatic / advanced colorectal cancer clinically effective? A systematic review.Adjuvant therapies for colorectal cancer.Process map proposal for the validation of genomic biomarkers.DIHYDROPYRIMIDINE DEHYDROGENASE DEFICIENCY (DPD) IN GI MALIGNANCIES: EXPERIENCE OF 4-YEARS.Pharmacogenetic variants in the DPYD, TYMS, CDA and MTHFR genes are clinically significant predictors of fluoropyrimidine toxicityHypermethylation of the DPYD promoter region is not a major predictor of severe toxicity in 5-fluorouracil based chemotherapy.Colon Cancer Cells Gene Expression Signature As Response to 5- Fluorouracil, Oxaliplatin, and Folinic Acid Treatment.Screening of dihydropyrimidine dehydrogenase genetic variants by direct sequencing in different ethnic groups.Pharmacogenetics of drug metabolizing enzymes and transporters: effects on pharmacokinetics and pharmacodynamics of anticancer agents.Emergency use of uridine triacetate for the prevention and treatment of life-threatening 5-fluorouracil and capecitabine toxicity.Breast cancer, DPYD mutations and capecitabine-related ileitis: description of two cases and a review of the literature.Delayed Presentation of DPD Deficiency in Colorectal Cancer.Pharmacogenomics of fluorouracil -based chemotherapy toxicity.Therapeutic drug monitoring of 5-fluorouracil.MicroRNA-494 sensitizes colon cancer cells to fluorouracil through regulation of DPYD.Systemic Combination Chemotherapy in Elderly Pancreatic Cancer: a Review.DPYD gene polymorphisms are associated with risk and chemotherapy prognosis in pediatric patients with acute lymphoblastic leukemia.5-Fluorouracil toxicity and dihydropyrimidine dehydrogenase enzyme: implications for practice.Association and prediction of severe 5-fluorouracil toxicity with dihydropyrimidine dehydrogenase gene polymorphisms: A meta-analysis.Clinical importance of risk variants in the dihydropyrimidine dehydrogenase gene for the prediction of early-onset fluoropyrimidine toxicity.Determining the optimal 5-FU therapeutic dosage in the treatment of colorectal cancer patientsA well-tolerated 5-FU-based treatment subsequent to severe capecitabine-induced toxicity in a DPD-deficient patient.The value of dihydrouracil/uracil plasma ratios in predicting 5-fluorouracil-related toxicity in colorectal cancer patients.Variants in the dihydropyrimidine dehydrogenase, methylenetetrahydrofolate reductase and thymidylate synthase genes predict early toxicity of 5-fluorouracil in colorectal cancer patients.Correlation between thymidylate synthase gene variants, RNA and protein levels in primary colorectal adenocarcinomas.Gender-specific elimination of continuous-infusional 5-fluorouracil in patients with gastrointestinal malignancies: results from a prospective population pharmacokinetic study.Dihydropyrimidine dehydrogenase gene variation and severe 5-fluorouracil toxicity: a haplotype assessment.The Herb-Drug Pharmacokinetic Interaction of 5-Fluorouracil and Its Metabolite 5-Fluoro-5,6-Dihydrouracil with a Traditional Chinese Medicine in Rats.DPYD genotype-guided dose individualization to improve patient safety of fluoropyrimidine therapy: call for a drug label update.A new sample preparation and separation combination for the precise, accurate, and simultaneous determination of uracil and dihydrouracil in human plasma by reversed-phase HPLC.Life-Threatening Reaction with Topical 5-Fluorouracil.DPYD*2A and MTHFR C677T predict toxicity and efficacy, respectively, in patients on chemotherapy with 5-fluorouracil for colorectal cancer.
P2860
Q33405398-138397E8-8482-4193-A228-61E6F9D3D4D6Q33432892-7A5386F8-7230-4993-9089-C52F179B4DBFQ33733501-CDB84AC7-0A86-4813-BF5A-C207613DD8C4Q34008793-8118743C-9DEA-4E09-84A6-A8E5502310D5Q34210342-1BBC163C-ACFE-4992-BD87-202FB4C4E2E0Q34216563-DF9C115D-1374-4760-97CB-3FDEFD453BDEQ34612932-20678EC2-929A-4826-A76B-862C43F6A818Q36007020-8F0D1F2D-6887-4392-B7E2-BFA4B787F99DQ36085299-FDF65D1D-E4E9-46F1-8CED-5AB760E7FDD0Q36177963-8ABF5EA1-5C59-4466-BBC1-5115D11C5094Q36555934-F65532AD-2AFB-4EC0-9BFE-261C78CD1ECBQ36927562-49436200-57A6-4A25-B757-0C84DDF3CD7EQ36959145-77CEBE50-44DD-402F-ADD7-36AC58CA0A0EQ36976499-0ECE8964-86D3-4DED-9B40-88A1C79B8431Q37030059-01158B32-580D-4A25-9CBF-1B724680CDE7Q37098042-775EECB6-15DF-43B5-B7E6-AA9FC582352BQ37163352-D497494F-99E3-4D76-BE25-A29692422234Q37595951-D16139BC-AE65-4EEB-8B92-A03FE63477B7Q37711732-4BBA82ED-5746-4231-8730-886991A39044Q38236614-2A19DD48-52CD-4745-8153-2E70DCA756F3Q38387640-DDDF2AC1-819E-4E8A-9E2F-5AC4ECFC6DA4Q38842633-1550B8CD-F98D-40AC-AD47-81EE889D559FQ38887255-AC1D64FC-244A-4945-B30E-523061D9C840Q38902171-F1139EAF-54DA-4F3B-8E75-4725854D5793Q40805012-FE605182-1752-4E9C-B964-0130206D7B98Q42045678-3270BAD7-4557-49BA-A44C-15FBDF939018Q42177462-97471DE3-3B18-4106-A5ED-152192309597Q42210747-432A70D1-FFC5-4C78-861B-1A728295EE44Q42316723-37DBE323-B589-46FC-BBF3-00DB10B569C5Q42388782-36BE9C62-B12B-42B8-879A-26CAB756B872Q42868390-5F415F24-58D8-4DC4-B6F9-4C167CC47BF0Q42916637-C9BDAF6D-FDD7-414D-9281-E2BFE67651EFQ43048728-B32DC282-0D57-498E-A37F-EA67DD80007AQ44716275-E8AC8D4B-FAE6-4132-AABB-52E51B0BC5B5Q45967307-15155216-70B8-453E-9AC2-78CBAFC09DBAQ47204428-B8DE1427-E871-42B4-A14E-5DAD3548F5C3Q47768032-019BB2E7-CE15-415E-B328-C066037A01AFQ48096902-4A3BAD92-EC43-4A0D-9AC3-E1CB0303F6C7Q48250453-894066DD-9C22-4884-BF16-985C09B1D359Q48310481-AE2BE3B5-7BA7-422D-9CEC-9FC6FB3C58BD
P2860
Dihydropyrimidine dehydrogenase deficiency, a pharmacogenetic syndrome associated with potentially life-threatening toxicity following 5-fluorouracil administration.
description
2004 nî lūn-bûn
@nan
2004年の論文
@ja
2004年論文
@yue
2004年論文
@zh-hant
2004年論文
@zh-hk
2004年論文
@zh-mo
2004年論文
@zh-tw
2004年论文
@wuu
2004年论文
@zh
2004年论文
@zh-cn
name
Dihydropyrimidine dehydrogenas ...... 5-fluorouracil administration.
@ast
Dihydropyrimidine dehydrogenas ...... 5-fluorouracil administration.
@en
type
label
Dihydropyrimidine dehydrogenas ...... 5-fluorouracil administration.
@ast
Dihydropyrimidine dehydrogenas ...... 5-fluorouracil administration.
@en
prefLabel
Dihydropyrimidine dehydrogenas ...... 5-fluorouracil administration.
@ast
Dihydropyrimidine dehydrogenas ...... 5-fluorouracil administration.
@en
P356
P1476
Dihydropyrimidine dehydrogenas ...... 5-fluorouracil administration.
@en
P2093
Hany Ezzeldin
Robert Diasio
P304
P356
10.3816/CCC.2004.N.018
P407
P577
2004-09-01T00:00:00Z